Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

As More Indian Companies Dive Into Biosimilars, Will Success In Generic Drugs Repeat?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In August, when leading Indian drug maker Dr. Reddy's Labs launched Cresp, a biosimilar brand of Amgen's darbepoetin alfa Aranesp, G.V.Prasad, Reddy's chief executive officer exulted at a media briefing that his company may well be on course to becoming the largest biologics player in the world in a few years, next only to Swiss giant Roche

You may also be interested in...



Business News, In Brief

Pfizer Lays Out Primary Care Business Development Opportunities

Business News, In Brief

Pfizer Lays Out Primary Care Business Development Opportunities

With Biocon Deal, Pfizer Expects To Gain First Mover Advantage In Global Biosimilar Insulin Market

MUMBAI - Months of widespread speculation over a likely deal between Pfizer and India's biotechnology flag-bearer Biocon finally came true as the two companies announced a comprehensive global commercialization pact to bring to market a range of insulins including analogs like glargine, aspart and lispro

Table

View full table

Tags:
Latest Headlines

Metsera Launches As New Obesity Contender Flush With $290m

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

See All
UsernamePublicRestriction

Register

SC073359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By